Additional file 4: of A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study

Yoo, Dae; Racewicz, Artur; Brzezicki, Jan; Yatsyshyn, Roman; Arteaga, Edgardo; Baranauskaite, Asta; Abud-Mendoza, Carlos; Navarra, Sandra; Kadinov, Vladimir; Sariego, Irmgadt; Hong, Seung; Lee, Sung; Park, Won

doi:10.6084/m9.figshare.c.3627587_D4.v1

13075_2016_981_MOESM4_ESM.doc (49 kB)

Additional file 4: of A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study

journal contribution

posted on 2016-04-02, 05:00 authored by Dae Yoo, Artur Racewicz, Jan Brzezicki, Roman Yatsyshyn, Edgardo Arteaga, Asta Baranauskaite, Carlos Abud-Mendoza, Sandra Navarra, Vladimir Kadinov, Irmgadt Sariego, Seung Hong, Sung Lee, Won Park

Overview of treatment-related serious adverse events occurring by severity (n [%]). (DOC 49 kb)

Funding

CELLTRION Inc

History

Usage metrics

Keywords

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 4: of A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study

Funding

CELLTRION Inc

History

Usage metrics

Categories

Keywords

Licence

Exports